Abstract Brief Communication
Such antimicrobials as clindamycin, ciprofloxacin and trimethoprim/sulfamethoxazole have its role in community-acquired MRSA infections. However, the utility of ciprofloxacin is quite limited, because the bacterial resistance to ciprofloxacin rapidly increases. Moreover, patients to whom clindamycin is administered are at risk of Clostridium difficile infections.
According to many recommendations, vancomycin is an antimicrobial of the first choice in the treatment of MRSA infections. Maybe, it is a time to re-evaluate this.
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rEFErEncEs

dIscussIon
In the last year, the increase in MIC values to vancomycin was observed, and administration of higher doses of this drug is necessary to achieve its therapeutic serum concentrations, especially in patients suffering from pneumonia caused by MRSA. [2] However, MIC value of vancomycin above 1 μg/mL significantly predicts treatment failure and mortality. [3] The lowest MIC value had dalbavancin. This antimicrobial, with the convenient administration and long duration of action, is as effective as vancomycin in skin and subcutaneous tissue infections. [4] Moreover, dalbavancin successfully reduced MRSA in biofilm, which can be useful in biofilm-associated infections. [5] In our study, MIC values of vancomycin for 45 of 124 (36.2%) strains of MRSA were 1.5 μg/L. This value (MIC-creep) is related to significant increase of mortality in cases of infection caused by MRSA. [6] The MIC values of daptomycin and linezolid were lower than MIC of vancomycin. The observations of Molina and Huang [7] were similar, suggesting that the role of vancomycin in the treatment of serious S. aureus infections becomes ineffective.
